Chinese COVID-19 vaccine trial shows strong immune response in 960 volunteers
NCT ID NCT04649021
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 trial tested the BNT162b2 mRNA vaccine in 960 healthy Chinese adults aged 18 to 85. Participants received two doses of either the vaccine or a placebo, 21 days apart. The main goal was to check safety and measure the immune response, specifically neutralizing antibodies against SARS-CoV-2. Results showed the vaccine triggered a strong antibody response, supporting its use in this population.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BNT162b2 mRNA vaccine
What this could lead to
If successful, this could confirm that the BNT162b2 vaccine is safe and effective for Chinese populations, supporting its use in pandemic control.
What could go wrong
This is a Phase 2 trial with 960 participants, so results may not fully predict real-world effectiveness or rare side effects. The study is completed, but long-term data are still limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SARS COV-2 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Jiangsu Provincial Center for Disease Control and Prevention
Nanjing, 210009, China